A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Name: A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Published: 2021
License: Public Domain

National Cancer Institute (NCI) · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

leukemia lymphoma multiple-myeloma sars-cov-2

solid tumor malignancy, hematologic malignancy, leukemia, lymphoma, multiple myeloma, mrna-1273 vaccine, moderna, sars-cov-2, booster shot, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Related documents